Clinical trial Recruiting at 1 site Interventional Ages 22 to 70

SCC Deep Brain Stimulation for Bipolar Depression in Bipolar I Patients

Official title: Deep Brain Stimulation for Bipolar Depression: Assessing the Safety and Use of Intracranial Neurophenotyping of State Switches

Run by Icahn School of Medicine at Mount Sinai · NCT07745374 · Data updated 2026-11-12

A small study tests whether deep brain stimulation of the subcallosal cingulate can help people with bipolar I depression who have not improved with other treatments, while monitoring brain signals to watch for manic switches.

Quick facts

Study typeInterventional
Ages22 Years to 70 Years
SexAll
Enrollment5 (estimated)
SponsorIcahn School of Medicine at Mount Sinai
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedSeptember 21, 2026
Main results expectedOctober 2028
Study endsOctober 2028
Registry record updatedNovember 6, 2026
Trial IDNCT07745374 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 22-70 with Bipolar I disorder, a current major depressive episode lasting 12+ months, stable mania control, and treatment-resistant depression.

Probably not a fit

Patients without sustained depressive improvement or who experience significant adverse effects or manic relapse may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses bilateral deep brain stimulation of the subcallosal cingulate in adults with treatment-resistant bipolar I depression. It includes simultaneous monitoring of local field potentials in the SCC and amygdala to help track mood states and potential manic risk during stimulation. Participants must have a current major depressive episode of at least 12 months, stable mania control, and failure of at least four adequate antidepressant trials while on mood-stabilizing medication. The approach aims to establish safety, feasibility, and biomarkers for optimizing neuromodulation and personalizing therapy. The study employs the Medtronic Percept PC DBS system at the Mount Sinai centers in New York.

Why it matters

Potential benefit: If successful, patients could experience improved depressive symptoms with a framework to minimize manic risks during DBS.

How similar studies have gone: Prior DBS approaches for mood disorders have shown mixed results; this study explores a novel biomarker-driven approach for safety and efficacy in bipolar depression.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 22-70 years
* Ability to provide written informed consent
* Primary diagnosis of Bipolar I Disorder confirmed by SCID-5
* Current major depressive episode (MDE) of at least 12 months duration
* Stable control of mania for a minimum of 1 year
* Agreement to remain on current anti-mania medication regimen
* Hamilton Depression Rating Scale-17 (HDRS-17) score ≥20 at screening and baseline
* Young Mania Rating Scale (YMRS) score \<12 at screening and baseline
* Treatment-resistant depression: failure to respond to at least 4 adequate trials of antidepressant treatment in the current episode. Antidepressant treatments include: Medications (Must include 2 antidepressant medications from different pharmacological classes), Psychotherapy, ECT, repetitive transcranial magnetic stimulation (rTMS), IV ketamine or intra-nasal esketamine.
* All patients must be receiving at least one mood stabilizing medication at entry into the trial. Medication regimen must be stable for a minimum of 4 weeks before the baseline visit.
* Able to provide informed consent
* English-speaking
* Deemed suitable surgical candidate by neurosurgical evaluation
* Under care of treating psychiatrist willing to collaborate with study team
* Able to reside in New York Metropolitan area during first 6 months or willing/able to travel monthly to study site
* Provision of at least two emergency contacts age ≥22 residing within reasonable proximity

Exclusion Criteria

* Current manic or hypomanic episode (YMRS ≥12)
* Rapid cycling pattern (≥4 mood episodes in the past 12 months)
* Active suicidal ideation with intent or plan
* Suicide attempt within six months prior to baseline
* Current psychotic symptoms
* Primary diagnosis of schizophrenia, schizoaffective disorder, or other psychotic disorder
* History (current and/or lifetime) of one or more schizophrenia-spectrum or other psychotic disorders including: schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, and major depressive disorder with psychosis (unipolar or bipolar), and/or psychotic depression (unipolar or bipolar) (does not include psychosis occurring in the context of a manic episode of a subject with bipolar disorder)
* Substance use disorder (moderate or severe) within 6 months
* Presence of any type of dementia / Major Neurocognitive Disorder / significant cognitive impairment interfering with study participation
* Subject has had a prior VNS Therapy or deep brain stimulation (DBS) implant
* Subject has a diagnosis of Substance Use Disorder as defined by the DSM-V without sustained remission (12 months or longer)
* History of borderline or severe personality disorder, as determined by clinical judgment, which would significantly interfere with a subject's participation in the study
* Active primary diagnosis of one or more of the following disorders: obsessive-compulsive disorder, eating disorder, or post-traumatic stress disorder
* Cognitive or psychiatric deficit (e.g., amnesia, delirium) that in the investigator's judgment would interfere with the subject's ability to accurately complete study assessments
* Current or lifetime history of psychotic features in any major depressive episode (MDE)
* Treatment with another investigational device or investigational drugs
* Contraindications to MRI (metallic implants, claustrophobia unmanageable with anxiolytics)
* Contraindications to general anesthesia or neurosurgery
* Significant structural brain abnormalities precluding safe electrode placement
* Active infection or immunocompromised state
* Active unstable medial condition (diabetes, heart disease, hypertension, cancer, endocrine)
* BMI \>35; and/or CRP \>3
* Coagulopathy or anticoagulation that cannot be safely interrupted
* Pregnancy or planning pregnancy during study period
* Women of childbearing potential unwilling to use effective contraception
* Prisoners or institutionalized individuals
* Decisionally impaired individuals (unless previously consented when capacitated)
* Special status patients (employees, VIPs, celebrities, public figures) unless consented before special status known

Where it's running

  • Center for Advanced Circuit Therapeutics, Clinical Neurosciences Center, Mount Sinai West
    New York, New York, United States
    Recruiting

Study contacts

  • Principal investigator: Helen Mayberg, MD — Icahn School of Medicine at Mount Sinai
  • Study coordinator: Ellie Rapp
  • Email: ellie.rapp@mssm.edu
  • Phone: 646-493-1607

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.